scholarly journals Automatic Prediction and Assessment of Treatment Response in Patients with Hodgkin’s Lymphoma Using a Whole-Body DW-MRI Based Approach

Diagnostics ◽  
2020 ◽  
Vol 10 (9) ◽  
pp. 702
Author(s):  
Valentina Brancato ◽  
Marco Aiello ◽  
Roberta Della Pepa ◽  
Luca Basso ◽  
Nunzia Garbino ◽  
...  
Keyword(s):  
Treatment Response ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Response To Treatment ◽  
Whole Body ◽  
Positron Emission ◽  
End Of Treatment ◽  
Tumor Load ◽  
Magnetic Resonance Imaging Mri

The lack of validation and standardization represents the main drawback for a clear role of whole-body diffusion weighted imaging (WB-DWI) for prediction and assessment of treatment response in Hodgkin’s lymphoma (HL). We explored the reliability of an automatic approach based on the WB-DWI technique for prediction and assessment of response to treatment in patients with HL. The study included 20 HL patients, who had whole-body positron emission tomography (PET)/ magnetic resonance Imaging (MRI) performed before, during and after chemotherapy. Using the syngo.via MR Total Tumor Load tool, we automatically extracted values of diffusion volume (DV) and its associated histogram features by WB-DWI images, and evaluated their utility in predicting and assessing interim and end-of-treatment (EOT) response. The Mann–Whitney test followed by receiver operator characteristic (ROC) analysis was performed between features and their inter-time point percentage differences for patients having a complete or partial treatment response, revealing that several WB-DWI associated features allowed for prediction of interim response and both prediction and assessment of EOT response. Our proposed method offers huge advantages in terms of saving time and work, enabling clinicians to draw conclusions relating to HL treatment response in a fully automatic way, and encloses, also, all DWI advantages compared to PET/ computed tomography (CT).

scholarly journals Scatter Artifact with Ga-68-PSMA-11 PET: Severity Reduced With Furosemide Diuresis and Improved Scatter Correction

2018 ◽  
Vol 17 ◽  
pp. 153601211881174 ◽  
Author(s):  
Courtney Lawhn-Heath ◽  
Robert R. Flavell ◽  
David E. Korenchan ◽  
Timothy Deller ◽  
Spencer Lake ◽  
...  
Keyword(s):  
Scatter Correction ◽  
Emission Tomography ◽  
Whole Body ◽  
Correction Algorithm ◽  
Resonance Imaging ◽  
Positron Emission ◽  
Psma Pet ◽  
Magnetic Resonance Imaging Mri ◽  
Specific Membrane

Purpose: To assess the utility of furosemide diuresis and the role of an improved scatter correction algorithm in reducing scatter artifact severity on Ga-68- Prostate-specific membrane antigen (PSMA)-11 positron emission tomography (PET). Materials and Methods: A total of 139 patients underwent Ga-68-PSMA-11 PET imaging for prostate cancer: 47 non-time-of-flight (non-TOF) PET/computed tomography, 51 PET/magnetic resonance imaging (MRI) using the standard TOF scatter correction algorithm, and 41 PET/MRI using an improved TOF scatter correction algorithm. Whole-body PET acquisitions were subdivided into 3 regions: around kidneys; between kidneys and bladder; and around bladder. The images were reviewed, and scatter artifact severity was rated using a Likert-type scale. Results: The worst scatter occurred when using non-TOF scatter correction without furosemide, where 42.1% of patients demonstrated severe scatter artifacts in 1 or more regions. Improved TOF scatter correction resulted in the smallest percentage of studies with severe scatter (6.5%). Scatter ratings by region were lowest using improved TOF scatter correction. Furosemide reduced mean scatter severity when using non-TOF and standard TOF. Conclusions: Both furosemide and scatter correction algorithm play a role in reducing scatter in PSMA PET. Improved TOF scatter correction resulted in the lowest scatter severity.

ROLE OF CD163+ TUMOUR ASSOCIATED MACROPHAGES IN PROGNOSTICATION OF PATIENTS DIAGNOSED OF HODGKIN'S LYMPHOMA: A PROSPECTIVE COHORT STUDY

2021 ◽  
pp. 9-10
Author(s):  
Akshay Sharma ◽  
Anshu Sharma
Keyword(s):  
Cohort Study ◽  
Treatment Response ◽  
Prospective Cohort Study ◽  
Prospective Cohort ◽  
Hodgkin’S Lymphoma ◽  
Early Stage ◽  
Univariate Analysis ◽  
Hodgkin's Lymphoma ◽  
End Of Treatment ◽  
Advanced Stages

Hodgkin's lymphoma (HL) constitutes around 30% of all lymphomas . IPS is used for the risk stratication of advanced stage HL but it lack applicability to the early stage cases ..In this prospective cohort study, we aim to conrm the relationship between CD68+TumourAssociated macrophages with treatment response (interim as well as end of treatment) of HL treated with the standard chemotherapy and radiotherapy regimens. A total of 50 patients were recruited over a period of 18 months and the patients were followed up in the hematology clinic and interim treatment responses as well as end of treatment response were assessed. Correlation of the CD163+Tumour Associated Macrophages and the treatment response showed that the Higher Percentages of CD163+Tumour Associated Macrophages were associated with more advanced stages.. Univariate analysis showed that there was no signicant correlation of interim treatment response as well as end of treatment response with CD163+Tumour Associated macrophages levels .

The Role of F18-fluorodeoxyglucose Positron Emission Tomography in the Management of Relapsed or Refractory Hodgkin’s Lymphoma

2012 ◽  
Vol 08 (02) ◽  
pp. 111
Author(s):  
Amanda F Cashen ◽  
Keyword(s):  
Positron Emission Tomography ◽  
Hodgkin’S Lymphoma ◽  
Response Assessment ◽  
Autologous Stem Cell Transplant ◽  
Hodgkin's Lymphoma ◽  
Emission Tomography ◽  
Cell Transplant ◽  
Prognostic Information ◽  
Positron Emission

Positron emission tomography (PET) is widely used in the diagnosis and response assessment after first-line treatment of Hodgkin’s lymphoma (HL). For the approximately 30 % of patients who relapse or have refractory disease, PET can provide valuable prognostic information during second-line therapy, at the time of autologous stem cell transplant (ASCT). Retrospective studies performed over the past decade have consistently found a significant association between a positive PET scan after salvage chemotherapy for HL and progression-free and overall survival after ASCT. In fact, the predictive value of pre-transplant PET appears higher than that of more traditional clinical risk factors. Unfortunately, there is little data to recommend the best treatment course for patients who have a positive pre-ASCT PET, and few studies have addressed the role of PET in other relapsed/refractory HL settings.

scholarly journals Hodgkin’s lymphoma with HLH and complete remission with brentuximab-based therapy

2019 ◽  
Vol 12 (12) ◽  
pp. e231629
Author(s):  
Blaine Knox ◽  
Daulath Singh ◽  
Hanh Mai ◽  
Kamran Mirza
Keyword(s):  
Bone Marrow ◽  
Hodgkin’S Lymphoma ◽  
Mediastinal Lymph Node ◽  
Lymph Node Biopsy ◽  
Brentuximab Vedotin ◽  
Hodgkin's Lymphoma ◽  
Positron Emission ◽  
End Of Treatment ◽  
Minimal Improvement ◽  
Epstein Barr

A 63-year-old man presented to the hospital with generalised weakness, fatigue and a 22 kg weight loss 4 months after being diagnosed with sarcoidosis on a mediastinal lymph node biopsy, with minimal improvement in symptoms on prednisone and methotrexate therapy. On arrival, he was found to have a haemoglobin of 57 g/L and platelet count of 82×109/L. Further work-up revealed six of eight diagnostic criteria for haemophagocytic lymphohistiocytosis (HLH): fever >38.9°C, splenomegaly, cytopaenia, hypertriglyceridaemia, haemophagocytosis and elevated ferritin >31 000 ng/mL. He was also found to have Epstein-Barr viraemia with greater than 17 000 copies. Bone marrow biopsy showed the presence of haemophagocytic histiocytes and evidence of classic Hodgkin’s lymphoma. He was started on HLH-94 protocol. Later treatment was switched to lymphoma-directed therapy and he finished six cycles of A+AVD (brentuximab vedotin, doxorubicin, vinblastine and dacarbazine) with end-of-treatment positron emission tomography/CT and bone marrow negative for lymphoma.

scholarly journals ROLE OF VITAMIN D3 LEVELS IN PROGNOSTICATION OF PATIENTS DIAGNOSED OF HODGKIN'S LYMPHOMA: A PROSPECTIVE COHORT STUDY

2020 ◽  
pp. 1-3
Author(s):  
Akshay Sharma ◽  
Abhimanyu Patial
Keyword(s):  
Cohort Study ◽  
Treatment Response ◽  
Prospective Cohort Study ◽  
Vitamin D3 ◽  
Prospective Cohort ◽  
Hodgkin’S Lymphoma ◽  
Early Stage ◽  
Univariate Analysis ◽  
Hodgkin's Lymphoma ◽  
End Of Treatment

Hodgkin’s lymphoma (HL) constitutes around 30% of all lymphomas(1). IPS is used for the risk stratification of advanced stage HL but it lack applicability to the early stage cases(1)..In this prospective cohort study, we aim to confirm the relationship between vitaminD3 levels with treatment response (interim as well as end of treatment) of HL treated with the standard chemotherapy and radiotherapy regimens. A total of 50 patients were recruited over a period of 18 months and the patients were followed up in the hematology clinic and interim treatment responses as well as end of treatment response were assessed. Correlation of the vitaminD3 levels and the treatment response showed that the low levels of vitaminD3 were associated with more advanced stages. Univariate analysis showed that there was no significant correlation of interim treatment response as well as end of treatment response with vitamin D3 levels.

ROLE OF SERUM LDH LEVELS IN PROGNOSTICATION OF PATIENTS DIAGNOSED OF HODGKIN'S LYMPHOMA: A PROSPECTIVE COHORT STUDY

2021 ◽  
pp. 13-15
Author(s):  
Akshay Sharma ◽  
Anshu Sharma
Keyword(s):  
Cohort Study ◽  
Treatment Response ◽  
Prospective Cohort Study ◽  
Prospective Cohort ◽  
Hodgkin’S Lymphoma ◽  
Early Stage ◽  
Univariate Analysis ◽  
Hodgkin's Lymphoma ◽  
End Of Treatment ◽  
Advanced Stages

Hodgkin's lymphoma (HL) constitutes around 30% of all lymphomas . IPS is used for the risk stratication of advanced stage HL but it lack applicability to the early stage cases ..In this prospective cohort study, we aim to conrm the relationship between hsCRP levels with treatment response (interim as well as end of treatment) of HL treated with the standard chemotherapy and radiotherapy regimens. A total of 50 patients were recruited over a period of 18 months and the patients were followed up in the hematology clinic and interim treatment responses as well as end of treatment response were assessed. Correlation of the serum LDH levels and the treatment response showed that the low levels of serum LDH level were associated with more advanced stages.. Univariate analysis showed that there was no signicant correlation of interim treatment response as well as end of treatment response with serum LDH levels .

ROLE OF CD68+ TUMOUR ASSOCIATED MACROPHAGES IN PROGNOSTICATION OF PATIENTS DIAGNOSED OF HODGKIN'S LYMPHOMA: A PROSPECTIVE COHORT STUDY

2021 ◽  
pp. 11-12
Author(s):  
Akshay Sharma ◽  
Anshu Sharma
Keyword(s):  
Cohort Study ◽  
Treatment Response ◽  
Prospective Cohort Study ◽  
Prospective Cohort ◽  
Hodgkin’S Lymphoma ◽  
Early Stage ◽  
Univariate Analysis ◽  
Hodgkin's Lymphoma ◽  
End Of Treatment ◽  
Advanced Stages

Hodgkin's lymphoma (HL) constitutes around 30% of all lymphomas . IPS is used for the risk stratication of advanced stage HL but it lack applicability to the early stage cases ..In this prospective cohort study, we aim to conrm the relationship between CD68+TumourAssociated macrophages with treatment response (interim as well as end of treatment) of HL treated with the standard chemotherapy and radiotherapy regimens. A total of 50 patients were recruited over a period of 18 months and the patients were followed up in the hematology clinic and interim treatment responses as well as end of treatment response were assessed. Correlation of the CD68+Tumour Associated Macrophages and the treatment response showed that the Higher Percentages of CD68+Tumour Associated Macrophages were associated with more advanced stages.. Univariate analysis showed that there was no signicant correlation of interim treatment response as well as end of treatment response with CD68+Tumour Associated macrophages levels .

Sign in / Sign up

Export Citation Format

Share Document